Rituximab, but not other antirheumatic therapies, is associated with impaired serological response to SARS- CoV-2 vaccination in patients with rheumatic diseases
- PMID: 33975857
- DOI: 10.1136/annrheumdis-2021-220604
Rituximab, but not other antirheumatic therapies, is associated with impaired serological response to SARS- CoV-2 vaccination in patients with rheumatic diseases
Keywords: COVID-19; antirheumatic agents; rituximab; vaccination.
Conflict of interest statement
Competing interests: RS has received research funding from GlaxoSmithKline, Genentech /Roche, Novartis, Corbus Pharmaceuticals, Boehringer Ingelheim Pharmaceuticals, InflaRx, Sanofi, Formation Biologics, Pharmaceuticals, and Kadmon, and has consulted for Formation Biologics, Glaxosmthkline, Janssen Pharmaceuticals, Sanofi Aventis, Chemocentryx, Abbvie and Regeneron. DJ-K owns stock in Cytodyn, GW pharmaceuticals, Astrazeneca and Walgreens.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous